Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (54${count})

  • Biomarkers, 2009
    Development of an alpha6*-Selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker

    Objective/Rationale
    The availability of a selective PET radiotracer for the drug target is critical for determining receptor occupancy in humans. NNR subtypes containing the alpha? subunit have been...

  • Therapeutics Development Initiative, 2008
    Development of ERb agonists for the treatment of Parkinson's Disease

    Objective/Rationale:
    Estrogens modulate many cerebral functions such as mental state, mood, cognition and locomotion. Data indicate that estrogens may slow down the development and progression of PD...

  • Clinical Intervention Awards, 2007
    Serotonin and Sleep Disordered Breathing in Parkinson Disease

    Objective/Rationale:
    Sleep related problems are a major cause of impairment in Parkinson's disease. Recent studies indicate a high incidence of a disabling sleep disorder – sleep disordered breathing...

  • Rapid Response Innovation Awards, 2014
    Levodopa Versus Dopamine Agonist after Deep Brain Stimulation in Parkinson's Disease

    Study Rationale:                   
    Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for patients with advanced Parkinson's disease (PD). STN DBS improves motor...

  • Repositioning Drugs for PD, 2011
    Duloxetine Hydrochloride as a Novel Neuroprotective Treatment for Parkinson's Disease

    Objective/Rationale: 
    In Parkinson’s disease (PD) dopaminergic neurons in the midbrain region substantia nigra pars compacta die. There is currently no treatment available that prevents this cell death...

  • LRRK2 Cohort Consortium, 2013
    Gender Differences in LRRK2 Mutation and Non-LRRK2 Mutation PD, and Expression of LRRK2 Mutations

    Objective/Rationale:
    In Western populations, men are approximately 1.5 times more likely to develop Parkinson’s disease (PD) than women. Furthermore, epidemiologic and clinical features of PD vary...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.